The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

Abstract

Across five trials of ustekinumab-treated patients with psoriasis, no cases of LTBI reactivation were observed in patients receiving concomitant INH prophylaxis for LTBI. INH prophylaxis was generally well tolerated by these patients with psoriasis.